`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`BRECKENRIDGE PHARMACEUTICAL, INC.,
`Petitioner,
`
`RESEARCH CORPORATION TECHNOLOGIES, INC.,
`Patent Owner.
`
`Case No. IPR2016-01242
`
`Patent No. RE 38,551
`
`PATENT OWNER’S UPDATED MANDATORY NOTICES
`
`UNDER 37 C.F.R. § 42.8
`
`
`
`Patent No. RE 38,551
`
`Case No. lPR2016—0l242
`
`Pursuant
`
`to 37 C.F.R.
`
`§ 42.8, Patent Owner Research Corporation
`
`Technologies, Inc. submits the following Updated Mandatory Notices to provide
`
`an update regarding related matters involving RE 38,551. All other information
`
`remains unchanged.
`
`A.
`
`Related Matters Under 37 C.F.R. § 42.8(b)(2)
`
`The related judicial proceedings involving RE 38,551 are shown below. On
`
`August 12, 2016, an Order issued in l:l3—cv—0l206—LPS (consolidated) (Ex. 2004),
`
`intending to enter final judgment for the plaintiffs/patent owner against
`
`the
`
`defendants consistent with the Memorandum Opinion unsealed on August 15, 2016
`
`(EX. 2003). See, e. g., Ex. 2003 at 86-91.
`
`
`
`
`
`
`, Disgition »
`..
`g
`A
`.
`5
`CaseCaption*«
`P
`
`UCB, Inc. et al. v. Teva Pharmaceuticals USA Inc.
`closed
`
`et al., 1:13-cv—0l 148-LPS (D. Del.)
`UCB, Inc. et al. V. Accord Healthcare Inc. et al., —l pending
`l:l3—cv—0l206—LPS (D. Del.)
`___l
`UCB, Inc. et al. v. Alembic Pharmaceuticals Ltd,
`1:l3—cv—01207-LPS (D. Del.)
`UCB, Inc. et al. v. Amneal Pharmaceuticals, LLC
`ez‘ al., l:l3—cv-0l208—LPS (D. Del.)
`UCB, Inc. et al. v. Apotex Corp. et al., 1:13-cv—
`Ol209—LPS (D. Del.)
`UCB, Inc. et al. v. Aurobindo Pharma Ltd. et al.,
`l:13—cv-01210-LPS (D. Del.)
`UCB, Inc. et al. v. Breckenridge Pharmaceutical
`Inc. et al., l:l3—cv—0l2ll-LPS (D. Del.)
`
`pending, consolidated with
`l:l3—cv—0l206—LPS (D. Del.)
`pending, consolidated with
`l:l3—cv—0l206—LPS (D. Del.)
`pending, consolidated with
`l:l3—cv~Ol206-LPS (D. Del.)
`pending, consolidated with “"1
`l:l3—cv—0l206—LPS (D. Del.)
`pending, consolidated with
`l:l3—cv—0l206—LPS (D. Del.)
`
`UCB, Inc. et al. v. Glenmark Generics Inc. USA et
`
`al., 1:13-cv-0l2l2—LPS (D. Del.)
`UCB, Inc. et al. v. Hetero USA Inc. et al., l:l3~cv-
`01213-LPS (D. Del.)
`
`| Closed
`| closed
`
`
`
`Patent No. RE 38,551
`
`Case No. IPR20l6-01242
`
`I
`e
`”
`Case Caption
`UCB, Inc. et al. v. Mylan Pharmaceuticals Inc. et
`al., l:l3—cV-01214-LPS (D. Del.)
`UCB, Inc. et al. v. Ranbaxy Laboratories Ltd. et
`
`L
`.
`LDisp0sition
`pending, consolidated with
`l:13—cv—Ol206-LPS (D. Del.)
`iclosed
`
`I
`
`J
`
`al., 1:13-CV-O12l5—LPS (D. Del.)
`UCB, Inc. et al. v. Sandoz Inc, l:l3-cv—012l6-
`LPS (D. Del.)
`
`closed
`
`UCB, Inc. et al. v Scz'eGen Pharmaceuticals Inc. et Closed
`al., 1:13-CV-01217-LPS (D. Del.)
`4
`UCB, Inc. et al. v Sun Pbarma Global FZE et al.,
`
`pending, consolidated with
`
`l:l3—cV—0l206-LPS (D. Del.)
`lpending, consolidated with
`l:13—cv—Ol206-LPS (D. Del.)
`pending, consolidated with I
`l:13—cv—Ol206-LPS (D. Del.) 4
`pending, consolidated with
`l:13—cv—Ol206-LPS (D. Del.)
`closed
`
`L121?)-CV-01218-LPS (D. Del.)
`UCB, Inc. et al. v. Watson Laboratories Inc. -
`Florida et al., 1:l3—cv—0l219—LPS (D. Del.)
`UCB, Inc. et al. v. Zydus Plzarmaceuticals (USA)
`Inc. ct al., 1:13-cv-0l220—LPS (D. Del.)
`UCB, Inc. et al. v. Apotex Corp. et al., 1:14-cV—
`00834—LPS (D. Del.)
`UCB, Inc. et al. v. Sun Pbarma Global FZE et al.,
`1:13-cV—055l4 (N.D. Ill.)
`
`UCB, Inc. et al. v. Zydus Pharmaceuticals (USATI Closed
`
`Inc. et al., 3:13-cv—0402l (D.N.J.)
`UCB, Inc. et al. V. Aurobindo Plzarma Lta’. et al.,
`l:16—cV-00451 (D. Del.)
`UCB, Inc. et al. v. Hetero USA Inc. et al., l:l6—cV— pending
`00452 (D. Del.)
`
`pending
`
`
`
`Patent No. RE 38,551
`
`Case No. IPR2016-01242
`
`Date: August 19, 2016
`
`Respectfully submitted,
`
`ggga
`
`ndrea G. Reister
`
`Registration No. 36,253
`Jennifer L. Robbins
`
`Registration No. 61,163
`COVINGTON & BURLING LLP
`
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001
`(202) 662-6000
`Attorneys for Patent Owner
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6, I hereby certify that on this 19th day of August
`
`2016, the foregoing Patent Owner’s Updated Mandatory Notices Under 37
`
`C.F.R. § 42.8 was served by electronic mail, by agreement of the parties, on the
`
`following counsel of record for Petitioner.
`
`Matthew L. F edowitz (rnfedowitz@merchantgould.com)
`Daniel R. Evans (devans@rnerchantgou1d.com)
`Merchant & Gould P.C.
`
`1900 Duke Street, Suite 600
`Alexandria, VA 22314
`
`Date: August 19, 2016
`
`4%
`
`Jennifer L. Robbins, Esq.
`Registration No.: 61,163